Clinical Relevance of the Interaction When Switching Non-Nucleoside Reverse Transcriptase Inhibitors in Patients Infected with HIV

ISSN: 2212-3938 (Online)
ISSN: 1574-8847 (Print)


Volume 9, 4 Issues, 2014


Download PDF Flyer




Current Clinical Pharmacology

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Arduino A. Mangoni
Flinders University and Flinders Medical Centre
Adelaide, SA
Australia


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Clinical Relevance of the Interaction When Switching Non-Nucleoside Reverse Transcriptase Inhibitors in Patients Infected with HIV

Author(s): Eric Dailly, Clotilde Allavena, Guillaume Deslandes, Regis Bouquie, Pascale Jolliet and Francois Raffi

Affiliation: Laboratoire de Pharmacologie Clinique, Hotel Dieu, 9 Quai Moncousu, 44093 Nantes Cedex, France.

Abstract

Substitution of a non-nucleoside reverse transcriptase inhibitor (NNRTI) with another drug of the same class combined with nucleoside reverse transcriptase inhibitors is a therapeutic strategy that can improve the tolerability of antiretroviral treatment. According to the pharmacokinetic properties of NNRTIs, this substitution generates pharmacokinetic drug interactions between NNRTIs, which could decrease NNRTI exposure and virological efficacy during the introductory phase of the new NNRTI. Pharmacokinetics and clinical data are reviewed to estimate the risk for switching from efavirenz to nevirapine, efavirenz to etravirine, efavirenz to rilpivirine and nevirapine to rilpivirine.

Keywords: Efavirenz, etravirine, nevirapine, rilpivirine, switch.

Purchase Online Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 9
Issue Number: 4
First Page: 399
Last Page: 403
Page Count: 5
DOI: 10.2174/1574884708666131111210258
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science